A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)
Time frame: Up to ~18 months
Secondary Endpoints
ORR- Investigator Assessed
Time to Response (TTR)- BICR
Duration of Response (DOR)- BICR
Eligibility Criteria
Inclusion Criteria: * Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer. * Has metastatic disease that has progressed during or following previous treatment appropriate for the disease type * Presence of radiographically measurable disease. * Is willing to provide tumor tissue * Has adequate organ function * Has a negative test or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C. * Has completed all prior therapy. * Female subjects of childbearing potential must have a negative serum pregnancy test. * Both male and female subjects must be willing to use adequate contraception. Exclusion Criteria: * Has peripheral neuropathy of Grade \>1. * Has a malignancy involving the central nervous sy…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →